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Summary
Background: Membrane trafficking of G protein-coupled
receptors (GPCRs) is crucial for temporal and spatial control
of cell-surface GPCR signaling. Receptor internalization is a
well-documented method cells use for regulating a wide
variety of GPCRs following their exposure to agonists.
Results: We report that, upon agonist stimulation, a GPCR
called vasoactive intestinal peptide receptor 2 (VPAC2) is
shed, rather than being internalized, in vitro and in vivo, from
the membrane of primary cilia—solitary hair-like organelles
that project from the cell surface. VPAC2 is released into the
extracellular milieu in the form of ciliary ectosomes that are
devoid of exosome markers. The agonist-induced VPAC2
shedding is selective, as shown by the fact that other ciliary
membrane proteins including two ciliary GPCRs are not
shed with VPAC2. VPAC2 ectosome shedding is dependent
on several components of endosomal sorting complexes
required for transport (ESCRT), including a subset of
ESCRT-III, VPS4, and LIP5. Agonist-stimulated VPAC2 is
important for ciliary-ectosome generation because it allows
VPS4 and LIP5 to transiently accumulate in primary cilia.
Shedding of VPAC2 from the ciliary surface results in termi-
nation of intracellular VPAC2 signaling.
Conclusions: Agonist-induced GPCR shedding from the
ciliary surface may represent an additional mode of GPCR
trafficking and signal regulation.
Introduction
G protein-coupled receptors (GPCRs) comprise a superfamily
of seven transmembrane receptors that mediate a variety of
cellular responses. Sustained stimulation by agonists induces
the removal of many activated GPCRs from the cell surface.
Reports over the past several decades have shaped our
understanding of the molecular mechanisms underlying the
removal of activated GPCRs from the cell surface, and
clathrin-dependent endocytosis has been identified as one
mechanism involved in this process [1, 2].
Primary cilia are hair-like microtubule-based organelles that
project out from the cell surface of many mammalian cells.
They harbor membrane receptors, including several GPCRs,
as well as their downstream signaling targets, and therefore
function as signaling hubs [3, 4]. Although there is an emerging
understanding of the cellular mechanisms that target GPCRs
to cilia, little is known about whether ciliary GPCRs exit
cilia and about the mechanisms and consequences of ciliary
receptor exit.
Mammalian cells release small single-membrane vesi-
cles; these include exosomes released by exocytosis of
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from the plasma membrane [5, 6]. While there is no clear
evidence that mammalian primary cilia shed ectosomes,
Chlamydomonas flagella, which share structural and func-
tional similarities with mammalian primary cilia, are known to
shed ectosomes [7], raising the possibility that mammalian
primary cilia may do so as well.
Topologically similar membrane-sculpting processes,
including MVB biogenesis, cytokinesis, and HIV egress, are
mediated by the machinery of endosomal sorting complexes
required for transport (ESCRT) complexes [8–11], which have
recently been implicated in ectosome budding [12, 13]. ESCRT
machinery consists of a series of distinct protein complexes
(ESCRT-0, ESCRT-I, ESCRT-II, and ESCRT-III) and ESCRT-
associated proteins, including Alix, an AAA-ATPase VPS4,
and a VPS4 cofactor, LIP5; among them, ESCRT-III filaments
play a central role in membrane fission, and the VPS4 complex
facilitates this process [9, 10].
By exploring the fate of agonist-stimulated ciliary GPCRs,
we have found that the recently identified ciliary GPCR
vasoactive intestinal peptide receptor 2 (VPAC2) [14] is selec-
tively shed, both in vitro and in vivo, from suprachiasmatic
nuclei (SCN) primary cilia upon specific agonist stimulation.
VPAC2 is shed in the form of VPAC2-containing ectosomes
that are devoid of exosome markers. VPAC2 shedding is
dependent on several ESCRT components, including a subset
of ESCRT-III (CHMP3, CHMP4B, and CHMP4C), VPS4, and a
VPS4 cofactor, LIP5. Furthermore, agonist-stimulated VPAC2
is important for ciliary-ectosome generation because it allows
VPS4 and LIP5 to transiently accumulate in primary cilia.
Lastly, VPAC2 shedding results in the prolonged termination
of its signaling. Together, these data demonstrate ectosome
shedding from mammalian primary cilia, implicate a new
mode of agonist-induced GPCR removal from the cell surface,
and define an essential role of ESCRT-III and VPS4-LIP5 in the
process of ciliary GPCR shedding.
Results
VPAC2 Is Removed from SCN Primary Cilia upon
PACAP-27 Treatment In Vitro
We previously demonstrated that SCN and primary cultures
prepared from SCN regions harbor VPAC2-positive primary
cilia [14]. Under our culture conditions,w55% of rat SCN cells
possessed primary cilia andw95% of those cilia were VPAC2-
positive. In the course of determining the effect of ligand
treatment on the ciliary localization of endogenous VPAC2,
we found that a VPAC2 ligand, pituitary adenylate cyclase-
activating peptide 27 (PACAP-27), did not change the percent-
age of cells that possessed primary cilia; instead, it removed
VPAC2 from SCN primary cilia in a dose-dependent manner,
with the maximum effect occurring with 1 mM PACAP-27
(Figures 1A and 1B; Figure S1A available online).
Upon PACAP-27 Treatment, VPAC2 Is Shed into the
Extracellular Milieu
To visualize the fate of the SCN VPAC2 protein after its expo-
sure to PACAP-27, we imaged live SCN cells expressing
C
TE
D
Mock
Arl13B
VPAC2
PACAP-27
Arl13B
VPAC2
A
Before PACAP-27 25 min 26 min 28 min 30 min 32 min
34 min 36 min 38 min 40 min 60 min
Arl13B-mCherryVPAC2-LAPC
E
D
mCherryVPAC2-LAP
35 minBefore PACAP-27
Ti
m
e 
(m
inu
tes
)
0
5
10
15
20
30
35
40
45
50
25
60
55
Start Finish
30 min26 min
B
%
 o
f c
ilia
te
d 
ce
lls
0
10
20
30
40
50
60
70
80
100
90
***
ailic
evitis
op
-2CAPVf
o
% 0
10
20
30
40
50
60
70
80
100
90
VPAC2
IFT88
AC3
Actin
Cells
Medium
(P100)
PACAP-27
- + - +
F
42 min
PACAP
-27
Mock PACAP
-27
Mock
Figure 1. VPAC2 Is Shed from SCN Primary Cilia into the Extracellular Milieu upon PACAP-27 Treatment In Vitro
(A) PACAP-27 treatment removes VPAC2 from SCN cilia. SCN cells were treated with mock solution or 1 mM of PACAP-27 for 1 hr and immunostained for
VPAC2 (green) and Arl13B (red). DNA was labeled with DAPI. Insets show unmerged images of the region around a cilium highlighted with a white arrow.
(B) SCN cells were treated and immunostained as in (A). The percentage of ciliated cells was plotted with respect to the cell number (left), and the percentage
of VPAC2-positive cilia was plotted with respect to the total number of cilia (right). Approximately 400 cells were counted for each treatment. Error bars
represent SD among three different coverslips. ***p < 0.001.
(C) VPAC2 is shed fromSCNcilia upon PACAP-27 treatment. A live SCN cell expressing VPAC2-LAP (LAP tag: S tag-cleavage site-GFP) and Arl13B-mCherry
was treated with 1 mM PACAP-27 at 0 min, and images were taken every minute for 1 hr (Movie S1).
(D) Boxplot showing the start and finish times of VPAC2 removal. SCN cells expressing VPAC2-LAP and Arl13B-mCherry were treated with 1 mMPACAP-27,
and 23 cilia were imaged every 2 min for 1 hr. The times at which the first and the last VPAC2-positive punctum deviated from cilia were designated as the
start and finish times (corresponding to 26 and 36 min, respectively, in C). The box represents the interquartile range, which contains 50% of values. The
(legend continued on next page)
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511both VPAC2-LAP and Arl13B-mCherry to mark the primary
cilium (the LAP tag consists of GFP followed by a cleavage
site for a protease and an S tag [LAP tag: S tag-cleavage
site-GFP]). Both proteins were localized to the cilium before
PACAP-27 treatment and ligand treatment gradually removed
VPAC2 from the cilium, leaving Arl13B unchanged (Figure 1C).
Byw26min after the addition of 1 mMPACAP-27, we observed
that VPAC2-LAP concentrated on particles that emerged from
the cilium, gradually drifted away from cilia, and eventually dis-
appeared from imaging fields (Figures 1C and 1D; Movie S1). It
is important to note that both 100 nM and 10 nM PACAP-27,
while affecting fewer VPAC2-positive cilia, showed the same
kinetics of VPAC2 shedding as 1 mMPACAP-27 treatment (Fig-
ure S1B), suggesting that agonist-induced VPAC2 shedding
occurs at physiological concentrations.
The removal pattern observed in Figure 1C suggested that
VPAC2 is disposed of into the extracellular space. Indeed,
imaging of live SCN cells expressing VPAC2-LAP, with cyto-
solic mCherry marking the cell boundary, showed the scat-
tered VPAC2 puncta located outside of the cell (Figure 1E).
N-terminal LAP-tagged VPAC2 showed similar removal
patterns (Figure S1C). We speculate that the one remaining
VPAC2-positive signal was in fact a shed particle that became
trapped near the ciliary base because it was not observed
when cells were fixed and washed extensively for immuno-
staining (Figure 1A) and because it was always close to the
cell (Figures 1E and S1C). Every VPAC2-positive punctum pre-
sent outside of cells could be traced back to the cilium, sug-
gesting that these puncta were coming strictly from the cilium.
Moreover, a newly developed anti-VPAC2antibody detected
endogenous VPAC2 in culture medium collected fromPACAP-
27-treated SCN cells, but not in culture medium collected from
mock-treated cells (Figure 1F). Because exosomes are known
to be released fromprimary neuron culture [15], actin (enriched
in exosomes [16]) was used in this study as a control to ensure
vesicle collections in both treatments. Taken together, these
results show that VPAC2 is shed into the extracellular space
upon PACAP-27 treatment in SCN in vitro.
These experiments also provided evidence that full-length
endogenous VPAC2 was removed upon agonist treatment
because themolecular weight of endogenous VPAC2 detected
in the culture medium was indistinguishable from that of
cell-associated VPAC2 (Figure 1F) and because both
C-terminal- and N-terminal-tagged VPAC2 proteins showed
similar removal patterns upon PACAP-27 treatment (Figures
1E and S1C).
PACAP-27 Shed VPAC2-Containing Ectosomes that Are
Devoid of Exosome Markers
Live imaging of SCN cells expressing VPAC2-LAP stained with
CellMask Orange, a plasma membrane dye that is slow to
internalize, showed that all shed VPAC2-positive puncta
were also positive for CellMask Orange, suggesting that
VPAC2 is shed in a membrane-bound form (Figure 2A and
Movie S2).
In addition, when VPAC2-containing particles from
100,0003 g centrifugation (P100) of PACAP-27-treated culture
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(E) A live SCN cell expressing VPAC2-LAP and cytosolic mCherry marking the
taken every 1 min for 1 hr. Representative merged time-lapse fluorescence im
(F) VPAC2, but not two other ciliary proteins, IFT88 and AC3, is detected in the
cells were treated with 1 mM PACAP-27 or mock solution for 1 hr. Cells and m
(A, C, and E) Scale bar represents 5 mm. See also Figure S1.medium were resuspended, loaded on the bottom of an iodix-
anol gradient, and centrifuged at 100,000 3 g for 18 hr to
equilibrium, VPAC2was found floating in fractions 8–11, corre-
sponding to densities of 1.104–1.154 g/ml (Figure 2B). These
fractions were devoid of all three exosome markers tested:
CD81 antigen (CD81), tumor susceptibility gene 101
(Tsg101), and ALG-2-interaction protein X (Alix) [17]; they
were found in fractions 4–5, corresponding to densities of
1.076–1.078 g/ml. Membranes and membrane-associated
proteins float upward in the gradient to a lower density, while
soluble or aggregated proteins remain at the bottom of the
gradient.
Negative staining and electron microscopic analysis (Fig-
ure 2C) showed vesicles in the VPAC2-positive fractions
(8–11 in Figure 2B). In addition, immunogold labeling of
VPAC2-positive fractions that were prepared fromSCN culture
transfected with LAP-VPAC2 by using anti-GFP antibody
showed immunogold particles associated with vesicles (Fig-
ures 2D and S2). Because size constraints likely make an
MVB-based exosome pathway within cilia infeasible, we
concluded that VPAC2 is shed in the form of VPAC2-contain-
ing ectosomes by outward budding from primary cilia mem-
branes, analogous to the recent report of Chlamydomonas
flagella bud ectosomes [7].
PACAP-27-Induced VPAC2 Shedding from Ciliary Surface
Is Highly Selective
Because Arl13B, a ciliary protein, is not removed with VPAC2
(Figure 1C), we suspected that VPAC2 might be selectively
shed from cilia. Indeed, we failed to detect IFT88, a component
of cilia, and AC3, a ciliary membrane protein, in medium
harvested from PACAP-27-treated SCN cells (Figure 1F). In
addition, live imaging of SCN cells expressing GFP-tagged
somatostatin receptor 3 (SSTR3-GFP) or SEP-tagged sero-
tonin receptor 6 (SEP-5HT6) showed no release of these ciliary
GPCRs over the entire hour of PACAP-27 treatment (Figures
3A and 3B), while VPAC2 ectosome shedding was evident by
the release of CellMask Orange-positive vesicles. These data
suggest that PACAP-27-induced VPAC2 removal from the
ciliary surface is highly selective.
VPAC2 Is Shed into the Extracellular Milieu upon
PACAP-27 Treatment In Vivo
PACAP-27-induced VPAC2 removal was also evident in vivo.
We treated postnatal day 4 (P4) rat pups intranasally for 1 hr
with PACAP-27, or with administration solution only, and
determined its effects on VPAC2 ciliary localization by immu-
nostaining SCN cryosections for endogenous VPAC2. Intra-
nasal application has been used previously to deliver PACAP
to rodents [18–20] and to humans [21], and PACAP can be
detected in the rat hypothalamus as early as 5–15 min after
administration [20]. Interestingly, we found that after a single
intranasal administration of PACAP-27, VPAC2 was removed
from SCN primary cilia in a dose-dependent manner, with the
maximum effect at 1 mg/animal (Figures 4A and 4B). Therefore,
in vivo, exogenous PACAP-27 induces VPAC2 removal from
SCN primary cilia.
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Figure 2. PACAP-27 Shed VPAC2-Containing Ectosomes that Are Devoid of Exosome Markers
(A) VPAC2 is associated with the membrane. SCN cells transfected with VPAC2-LAP (green) were labeled with a slow internalizing plasma membrane dye,
CellMask Orange (red), and treated with 1 mM PACAP-27. Time-lapse images were taken every 5 min for 1 hr. Representative fluorescence images of cells
before and after treatments are shown (Movie S2). Scale bar represents 5 mm.
(B) Fractionation of VPAC2-containing vesicles using iodixanol gradient. SCN cells were treated with 1 mM PACAP-27 for 1 hr. The medium was harvested
and subjected to differential centrifugation. Vesicles were loaded onto the bottom of an iodixanol gradient (5%–40%), and fractions were collected from the
top (1) to the bottom (14) of the tube following centrifugation. Fractions were blotted for VPAC2 and exosomal markers, including CD81 antigen (CD81),
tumor susceptibility gene 101 (Tsg101), and ALG-2-interaction protein X (Alix). VPAC2was detected in fractions 8–11, and exosomal markers were detected
in fractions 4–5.
(C) VPAC2-positive fractions contain vesicles. Fractions 8–11 from (B) were combined, precipitated at 100,000 3 g, subjected to negative staining, and
imaged under transmission electron microscope.
(D) Vesicles (fractions 8–11) harvested from PACAP-27-treated SCN cells transfected with LAP-VPAC2 were subjected to immunogold labeling with
anti-GFP antibody. The diameter of the gold particles is 15 nm. See also Figure S2.
(C and D) Scale bar represents 100 nm. Original magnification: 68,6003.TR
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512To test whether the removed VPAC2was shed into the extra-
cellular space in vivo, we intranasally administered P4 rat pups
with PACAP-27 and harvested hypothalami containing the
SCN region. Hypothalami were treated with papain to loosen
the extracellular matrix and release extracellular materials
into the solution, leaving cells intact; this procedure is widely
used for harvesting viable cells from fresh brain tissues and
has been recently used to harvest brain exosomes [22].
Harvested hypothalamic extracellular materials, which were
loaded onto the bottom of an iodixanol gradient and centri-
fuged at 100,000 3 g for 18 hr to equilibrium, showed
VPAC2-containing vesicles, devoid of exosome markers, in
fractions 8–10. This corresponds to densities of 1.104–
1.141 g/ml, similar to results from the primary SCN culture (Fig-
ure 4C, left). VPAC2-containing ectosomes were not detected
in P4 rat pupswith intranasalmock treatment (Figure 4C, right).
Taken together, these data demonstrate that exogenous
PACAP-27 causes VPAC2 shedding into the extracellular
milieu in the form of VPAC2-containing ectosomes in vivo.
PACAP is thought to be released from the retinohypo-
thalamic tract (RHT) that innervates the SCN [23]. RHT projec-
tions appear in rat SCN from P1 but will not reach adult levels
until P15 [24]. The concentration of endogenous PACAP-27 in
P4 SCN might be too low to produce a measurable effect,
R
E which explains why we failed to detect VPAC2 ectosomes inP4 rat pups without exogenous PACAP-27 treatment (Figures4C, right, and 4D). Consistent with the notion that RHT projec-tions reach adult levels at P15, we detected VPAC2-containing
ectosomes in extracellular materials harvested from P15 rat
hypothalami without exogenous PACAP-27 treatment (Figures
4D and 4E).
A Subset of ESCRT-III, VPS4, and the VPS4 Cofactor, LIP5,
Is Important for Agonist-Induced VPAC2 Ectosome
Shedding
Although not all ESCRT subunits are equally necessary
for ESCRT-dependent processes, ESCRT-III and VPS4-LIP5
work together to catalyze membrane fission [10] and have
been found to be always essential [25]. We therefore investi-
gated the role of ESCRT-III, VPS4, and LIP5 in VPAC2
shedding.
While humans express 12 different ESCRT-III proteins
(CHMP1A, CHMP1B, CHMP2A, CHMP2B, CHMP3, CHMP4A
(not present in rodents), CHMP4B, CHMP4C, CHMP5,
CHMP6, CHMP7, and IST1 [26]), RT-PCR analysis showed
that rat SCN cells do not express CHMP1B, CHMP2B,
CHMP5, CHMP6, and CHMP7 (Figure S3A). Most of these
ESCRT-III proteins were shown to act as dominant negative
CellMask Orange membrane dye
SEP-5HT6
CellMask Orange membrane dye
SSTR3-GFP
Before PACAP-27 26 min 30 min 60 min20 min
A B
Before PACAP-27 26 min 30 min 60 min20 min
Figure 3. VPAC2 Shedding into the Extracellular Milieu Is Selective
(A and B) Two ciliary GPCRs, somatostatin receptor 3 (SSTR3) and serotonin receptor 6 (5HT6), are not shed from SCN cilia upon PACAP-27 treatment. SCN
cells (n = 45) expressing SSTR3-GFP (green) or SEP-5HT6 (green) were labeled with CellMask Orange (red) and treated with 1 mM PACAP-27. Time-lapse
imageswere taken every 1min for 1 hr, and fluorescence images for representative time points are shown. Neither SSTR3 (A) nor 5HT6 (B) was removed from
cilia during the entire time course while shedding occurred, as evidenced by the release of CellMask Orange-labeled particles. Scale bar represents 5 mm.
TE
D
GPCR Shedding from the Ciliary Surface
513when C-terminally attached with a bulky tag [27, 28]. We
expressed all LAP-tagged human ESCRT-III proteins in rat
SCN cells and found that LAP-tagged hCHMP3, hCHMP4A,
hCHMP4B, and hCHMP4C conferred significant dominant-
negative effects on VPAC2 shedding (Figure S3B). Consis-
tently, partial knockdown of these CHMPs partially inhibited
VPAC2 shedding (Figures 5A and S3C).
Mammals express two VPS4 proteins: VPS4A and VPS4B
[29]. We found that expression of dominant-negative VPS4
mutant hVPS4AE228Q or hVPS4BE235Q [30] inhibited PACAP-
27-induced VPAC2 shedding in rat SCN cells, while wild-type
hVPS4A or hVPS4B did not (Figure S3D). Partial knockdown
of VPS4 or the VPS4 cofactor, LIP5, partially inhibited VPAC2
shedding in rat SCN cells (Figures 5B, 5C, and S3E). Neither
expression of dominant-negative forms nor partial knockdown
of these ESCRT proteins significantly affected ciliogenesis or
cilia length (data not shown). Taken together, we conclude
that a subset of ESCRT-III and VPS4-LIP5 is required for
VPAC2 shedding.
While we did not detect VPS4-LAP and LIP5-LAP in SCN
primary cilia before PACAP-27 treatment (Figures 5D, 5E,
and S3F), live imaging of rat SCN cells expressing hVPS4A-
LAP and VPAC2-mCherry showed VPS4A puncta in cilia
from w13 min after PACAP-27 treatment to just prior to
VPAC2 shedding (Figure 5D). VPS4A puncta after w18 min
were weaker in intensity and were more transient compared
to VPS4 puncta between 13 and 18 min. VPS4B and LIP5
showed similar spatiotemporal patterns in cilia (Figures S3F
and 5E). Because no VPAC2 puncta were associated with
VPS4A, VPS4B, or LIP5, we deduced that VPS4 and LIP5 are
only transiently accumulated in cilia upon PACAP-27 treat-
ment to facilitate VPAC2 shedding. Because LAP-tagged
CHMPs act as dominant negative (Figure S3B), spatiotemporal
patterns of CHMPs were not determined.
The Accumulation of VPS4 and LIP5 in Cilia upon
PACAP-27 Treatment Is Dependent on VPAC2
To determine whether VPAC2 is important for ectosome shed-
ding, we treated rat SCN cells with lentivirus-mediated rVPAC2
shRNAmiR that has been previously validated [14]: it reduces
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ASCN cell VPAC2 mRNA levels to 4% of that of control
shRNAmiR treatment and results in 0% VPAC2-positive cilia
in SCN culture. Knockdown of VPAC2 (Figure 6A) completely
abolished PACAP-27-induced shedding of ectosomes, as
evident by lack of CellMask Orange particle release, suggest-
ing that VPAC2 is required for PACAP-27-induced ciliary-
ectosome shedding.
Because VPS4 and LIP5 accumulated in cilia after PACAP-
27 treatment and are required for VPAC2 ectosome shedding,
we hypothesized that VPAC2 is important for VPS4 and LIP5
accumulation in cilia upon PACAP-27 treatment. Indeed,
upon PACAP-27 treatment, no VPS4A was detectable in the
cilia of cells pretreated with rVPAC2 shRNAmiR, while VPS4A
accumulated in the cilia of cells pretreated with control
shRNAmiR (Figure 6B). Knockdown of VPAC2 also abolished
PACAP-27-induced VPS4B and LIP5 accumulation in cilia (Fig-
ures S4 and 6C), suggesting that agonist-stimulated VPAC2 is
involved in transient accumulation of VPS4-LIP5 in cilia to
facilitate ciliary-ectosome shedding.
Agonist-Induced VPAC2 Shedding Leads to Long-Term
Termination of Intracellular VPAC2 Signaling
Our findings raised the question of the functional conse-
quences of VPAC2 shedding. We hypothesized that shedding
of VPAC2 from the ciliary surface would temporarily terminate
VPAC2-mediated signaling by removing active receptors from
cilia until newly produced VPAC2 proteins could reinstate
VPAC2 signaling capacity.
PACAP-27 binds to VPAC2 and to two of its homologs,
VPAC1 and PAC1. In situ hybridization analyses have shown
that rat SCN express VPAC2 and PAC1, but not VPAC1
[31, 32]. Using RT-PCR analysis, we confirmed the presence
of PAC1 and VPAC2 and the absence of VPAC1 in our SCN
cell cultures (data not shown). To determine the effect of
VPAC2 shedding on VPAC2-specific intracellular signaling in
SCN cells, we efficiently knocked down PAC1 using lenti-
virus-mediated rPAC1 shRNAmiR. Upon rPAC1 shRNAmiR
treatment, the PAC1 mRNA level was reduced to 4% of that
of control shRNAmiR treatment (Figure 7A) and PAC1 protein
was not detectable in western blot (Figure 7B). PAC1
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Figure 4. VPAC2 Is Released into the Extracellular Milieu upon PACAP-27 Treatment In Vivo
(A) Intranasal administration of PACAP-27 removes VPAC2 from SCN in vivo. P4 rats were treated intranasally with 0 mg, 0.25 mg, 0.5 mg, 0.75 mg, or 1 mg of
PACAP-27 for 1 hr. Brains were cryoembedded, sectioned, and immunostained for VPAC2 (green) and Arl13B (red). DNAwas labeled with DAPI. Insets show
unmerged images of the region around a cilium highlighted with a white arrow. Scale bar represents 5 mm.
(B) Cryosections were immunostained as in (A), and the percentage of VPAC2-positive cilia was plotted with respect to the total number of cilia. Error bars
represent SD among three different rat pups. ***p < 0.001.
(C) P4 rats were treated intranasally with 1 mg PACAP-27 (left) or mock solution (right) for 1 hr. Hypothalami were removed and treated with papain to loosen
the tissue. The medium was harvested and subjected to differential centrifugation. Vesicles were loaded on the bottom of an iodixanol gradient (5%–40%),
and fractionswere collected from the top (1) to the bottom (14) of the tube following centrifugation. Fractionswere blotted for VPAC2 and exosomalmarkers,
including CD81, Tsg101, and Alix. The signals detected in fractions 13–14may represent aggregates formed due tomechanical disruption of papain-treated
tissues in this set of experiments.
(D) VPAC2 was detected in extracellular materials harvested from hypothalami of P15 rats without exogenous PACAP-27 treatment. Hypothalami from P15
or P4 rat pups were removed and processed, and total lysate and extracellular materials (P100) were immunoblotted for VPAC2.
(E) Hypothalami from P15 rats were removed and processed, and extracellular materials were loaded onto the bottom of an iodixanol gradient (5%–40%).
Fractions were collected from the top (1) to the bottom (14) of the tube following centrifugation. Fractions were blotted for VPAC2 and two exosomal
markers, Tsg101 and Alix.
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514knockdown did not affect PACAP-27-induced VPAC2
shedding (data not shown).
To track VPAC2 signaling in these PAC1 knockdown SCN
cells, we followed the fate of phosphorylation of extracellular
signal-regulated kinase (p-ERK), the downstream signaling
target of VPAC2 stimulation, after PACAP-27 treatment.
Consistent with complete shedding of VPAC2 from treated
cells by w40 min, p-ERK peaked at 10 min and then disap-
peared after 40 min of continuous PACAP-27 treatment (Fig-
ure 7C, left). In contrast, PACAP-27 stimulation of VPS4 small
hairpin RNA (shRNA)-treated cells (in which VPAC2 sheddingwas partially inhibited) caused the p-ERK to peak at 10 min
and persist for 4 hr of continuous PACAP-27 treatment
(Figure 7C, right). Thus, the disappearance of agonist-
stimulated VPAC2 signaling is caused by receptor shedding
and not by PACAP-27 treatment directly.
Discussion
Until now, the prevailing mechanism known to remove
activated GPCRs from the cell surface has been receptor
endocytosis [1, 2]. Here, we demonstrate for the first time
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Figure 5. A Subset of ESCRT-III, VPS4, and the VPS4 Cofactor, LIP5, Is Important for Agonist-Induced VPAC2 Shedding
(A and B) Partial knockdown of CHMP3, CHMP4B, CHMP4C (A), or VPS4 (B) partially inhibits VPAC2 shedding. SCN cells infected with lentivirus containing
control shRNA and shRNAs against CHMP3, CHMP4B, CHMP4C, or VPS4were treated with 1 mMof PACAP-27 ormock solution. Cells were immunostained
for VPAC2 and Arl13B, and the percentage of VPAC2-positive cilia was plotted (left). Protein extracts were immunoblotted for CHMP3, CHMP4B, CHMP4C,
VPS4, and actin (right). About 63%CHMP3, 42%CHMP4B, 42%CHMP4C, and 65%VPS4 proteinswere depleted upon infection with corresponding shRNA
lentivirus compared to control virus. See also Figures S3A–S3E.
(C) Partial knockdown of LIP5 partially inhibits VPAC2 shedding. SCN cells infected with lentivirus containing control shRNA or LIP5 shRNA were treated
with 1 mM of PACAP-27 or mock solution. Cells were immunostained for VPAC2 and Arl13B, and the percentage of VPAC2-positive cilia was plotted
(left). mRNA levels were measured by qRT-PCR (right). Error bars (right) represent the SD of triplicate PCR assays. ***p < 0.001. GAPDH levels were
used as an internal control for normalization.
(A–C) Left:w300 cilia were counted for each treatment. ***p < 0.001.
(D and E) Upon treatment with PACAP-27, VPS4A-LAP (D) and LIP5-LAP (E) are detected in cilia fromw13 min until just prior to VPAC2 shedding. SCN cells
were transfected with VPS4A-LAP or LIP5-LAP together with VPAC2 mCherry and treated with 1 mM PACAP-27. Merged time-lapse fluorescence images
were taken from the region highlighted with a white box every 10 s for 30min. Representativemerged time-lapse fluorescence images before and after treat-
ment are shown. See also Figure S3F. Scale bar represents 5 mm.
R
ET
R
A
C
TE
D
GPCR Shedding from the Ciliary Surface
515that upon PACAP-27 stimulation, the ciliary GPCR VPAC2 is
shed from the SCN ciliary surface into the extracellular milieu
in the form of ectosomes, in vitro and in vivo, resulting in
termination of VPAC2-mediated intracellular signaling. Our
results strongly suggest that agonist-induced GPCR shedding
may represent another mode of GPCR surface removal for
signaling regulation.
Our study clearly demonstrates that mammalian primary
cilia shed ciliary ectosomes, and we begin to explain amechanism whereby late-acting ESCRT proteins—including
a subset of ESCRT-III, VPS4, and the VPS4 cofactor, LIP5—
are involved in VPAC2 ectosome shedding. We show that
PACAP-27 induces transient accumulation of VPS4 and LIP5
in cilia. Interestingly, ciliary-ectosome shedding does not
occur until about 26 min after PACAP-27 treatment, despite
the fact that VPS4 and LIP5 start to accumulate in cilia within
about 13 min once the treatment is administered. This may
indicate that VPS4 and LIP5 are important for remodeling
B
Before PACAP-27: 13 min
CellMask Orange membrane dye
Control shRNAmiR
Before PACAP-27: 13 min
VPAC2 shRNAmiR
A CellMask Orange membrane dye
PACAP-27: 30 minMock: 30 min
control shRNAmiR control shRNAmiR VPAC2 shRNAmiR
C
Before BeforePACAP-27: 14 min PACAP-27: 14 min
CellMask Orange membrane dye
Control shRNAmiR VPAC2 shRNAmiR
VPS4A-LAP LIP5-LAP
Figure 6. The Accumulation of VPS4 and LIP5 in Cilia upon PACAP-27 Treatment Is Dependent on VPAC2
(A) VPAC2 is important for ciliary-ectosome release. Cells pretreated with VPAC2 shRNAmiR did not release vesicles, whereas cells pretreated with mock
shRNAmiR released vesicles upon PACAP-27 treatment. SCN cells were infected with lentivirus containing control shRNAmiR or VPAC2 shRNAmiR, labeled
with CellMask Orange (red), and treated with 1 mM of PACAP-27 or mock solution. Time-lapse images were taken every 5 min for 1 hr. Representative
fluorescence images of cells 30 min after treatment are shown. Approximately 40 cilia were imaged from three different plates for each condition.
(B and C) Knockdown of VPAC2 abolished PACAP-27-induced VPS4A and LIP5 accumulation in cilia. SCN cells were pretreated with control shRNAmiR or
VPAC2shRNAmiR and transfected with VPS4A-LAP (B) or LIP5-LAP (C). Time-lapse images were taken every 1 min for 30 min after 1 mM PACAP-27
treatment. Images from the green channel of the region around the cilium are enlarged and shown in the bottom row. At least 40 cilia were imaged for
each condition. Upon PACAP-27 treatment, VPS4A-LAP or LIP5-LAP transiently accumulated to cilia in 88.3% (for VPS4A) or 87.5% (for LIP5) of cells
pretreated with control shRNAmiR but in 0% of cells pretreated with VPAC2 shRNAmiR. See also Figure S4.
(A–C) Scale bars represent 5 mm.R
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516ESCRT-III. We also show that PACAP-27-induced accumula-
tion of VPS4 and LIP5 in cilia requires VPAC2. Because other
ESCRT-dependent processes require early-acting ESCRT
proteins (ESCRT-0, ESCRT-I, ESCRT-II, or Alix), we feel that
it is unlikely that VPAC2 directly recruits VPS4-LIP5 to cilia.
Systematic evaluation of the importance of other ESCRT pro-
teins will help elucidate the exact mechanism of ciliary-
ectosome shedding.
Although PACAP is known to be contained in the RHT that
innervates the SCN via optic nerves and the optic tract [23],
the normal physiological response to endogenous PACAP
and the normal conditions triggering the release of PACAP
into SCN are not well established [33]. An exciting possibility
is that VPAC2 shedding is a specific response to PACAP-27
in SCN. If proven to be true, our findings would provide a basisfor further studies to help define when PACAP-27 is released
and to illuminate its role in SCN. PACAP-27, by inducing
VPAC2 shedding, may fine-tune VPAC2 signaling by control-
ling the number of receptors on cilia in vivo. Mice lacking
VPAC2 [34], or overexpressed with human VPAC2 [35], exhibit
altered circadian rhythms in locomotor behavior. In addition,
duplication of the VPAC2 gene in humans confers signi-
ficant risk of schizophrenia [36, 37]. As ectosomes shed
from Chlamydomonas flagella have biological function [7],
PACAP-27, by releasing VPAC2-containing ciliary ectosomes,
may also play a role in mediating intercellular signaling by
transferring VPAC2 or other molecules to recipient cells.
Ectosome release is likely a general feature of mammalian
primary cilia. It has been shown that neuroepithelial primary
cilia might be a source for prominin-1-containing membranes
A B C
Figure 7. Agonist-Induced VPAC2 Shedding Leads to Prolonged Termination of Intracellular VPAC2 Signaling
(A) PAC1mRNA levels were reduced byw99% in SCN cultures infected with lentivirus containing PAC1 shRNAmiR compared to cells infected with control
lentivirus. mRNA levels were measured by qRT-PCR. Error bars represent the SD of triplicate PCR assays. ***p < 0.001. GAPDH levels were used as an
internal control for normalization.
(B) Protein extracts from SCN cultures infected with control shRNAmiR or PAC1 shRNAmiR were immunoblotted for PAC1 and actin (loading control).
(C) Knockdown of VPS4A/VPS4B leads to persistence of p-ERK signaling. SCN cells pretreated with PAC1 shRNAmiR were treated with control shRNA (left)
or VPS4 shRNA (right) and treated with 1 mM PACAP-27 for 0 min, 10 min, 20 min, 30 min, 40 min, 60 min, and 4 hr. Cells were then lysed, harvested, and
blotted with p-ERK and ERK.
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517found in neural tube fluid [38] and that exosome-like vesicles
collected from urine are enriched in ciliary proteins [39];
though in the latter case it has been suggested that these
vesicles, rather than being shed, adhere to cilia. Other types
of membrane release from mammalian cilia have also been
reported. The rod outer segment, a specialized cilium of
photoreceptors, has been shown to shed aged membranous
discs at distal ends [40]. Cilia tips of retinal pigment epithelial
cell lines expressing mutant CEP162 become strikingly
swollen and release the bulging structures [41]. Further studies
are required to determine whether these membrane releases
are also dependent on ESCRT proteins.
In summary, our study provides the first molecular and
cellular insights into ESCRT-dependent, agonist-induced
GPCR-containing ectosome shedding from mammalian pri-
mary cilia. Current studies are underway to determine the
scope and extent of agonist-induced GPCR shedding
(whether it is widespread or a relatively specific phenomenon)
and to determine the in vivo consequences of its shedding.
Experimental Procedures
The complete details of the experimental procedures are provided in the
Supplemental Experimental Procedures.
Animals
Rats were purchased from Charles Rivers. Animal care and use were in
accordance with the National Institutes of Health Guide for the Care and
Use of Laboratory Animals and were approved by the Institutional Labora-
tory Animal Care and Use Committee at the University of Illinois at Chicago.
Intranasal Administration
Intranasal administration was performed according to the procedure
described previously [42] and was generally performed in the afternoon
(w2:00 p.m.). In short, 0.25 mg, 0.5 mg, 0.75 mg, or 1 mg of PACAP-27
(American Peptide Company) was dissolved in 5 ml of water. The solution
was administered intranasally to P4 rat pups (2.5 ml/nostril); 2.5 ml/nostril
of water was administered as the control.
Vesicle Floatation on Iodixanol Gradient
To harvest vesicles from SCN cells, medium was harvested and centri-
fuged at 300 3 g for 10 min and 2,000 3 g for 30 min to remove intact
and dead cells. The supernatant was spun at 15,000 3 g for 1 hr and
100,000 3 g for 1 hr (S110-AT fixed-angle rotor, Thermo Scientific). The
pellet was washed with PBS and spun again at 100,000 3 g for 1 hr to
obtain P100.
R
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AVesicle harvest from the rat hypothalamus was performed as described
previously [22], with the following modifications. Hypothalami from
rat pups were dissected, roughly chopped, and treated with papain
(Worthington) at 37C to loosen the extracellular matrix and to release extra-
cellular materials in solution. Papain-treated hypothalami were disrupted
with Dounce homogenizer, and homogenates were spun at 300 3 g for
10 min to remove cells. Supernatant was filtered through a 0.2 mm syringe
filter. Filtrate was spun at 2,000 3 g for 30 min, 15,000 3 g for 1 hr, and
100,000 3 g for 1 hr. The pellet was washed with PBS and spun again at
100,000 3 g for 1 hr.
Discontinuous iodixanol gradient was prepared as described [43]. Briefly,
solutions of 40%, 20%, 15%, 10%, 5%, and 0% iodixanol (w/v) were made
by diluting a stock solution of OptiPrep (60%w/v) (Sigma) in 0.25M sucrose/
10 mM Tris (pH 7.5). P100 pellets from SCN culture or hypothalami were
resuspended in 40% iodixanol (w/v) solution in 0.25 M sucrose/10 mM
Tris (pH 7.5) and were layered with 20%, 15%, 10%, and 5% iodixanol solu-
tions, followed by ultracentrifugation in S55S-1229 or S50-ST (Thermo
Scientific) at 100,000 3 g for 18 hr at 4C. The gradients were fractionated
into 14 fractions of equal volume from the top. Fractions were analyzed
immediately by standard SDS-PAGE and immunoblot analyses.
Supplemental Information
Supplemental Information includes Supplemental Experimental Proce-
dures, four figures, and two movies and can be found with this article online
at http://dx.doi.org/10.1016/j.cub.2014.01.010.
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